#USA #San Diego #Viking Therapeutics #VK2735 #ECO 2026

Viking Therapeutics Unveils VENTURE Oral Dosing Trial Results at ECO 2026

In a major presentation at the European Congress on Obesity (ECO) 2026 held in Istanbul, Viking Therapeutics, Inc. unveiled compelling data from its Phase 2 VENTURE-Oral Dosing trial for VK2735. This novel oral therapy aims to address obesity, showcasing its potential as a groundbreaking treatment option.

VK2735: A New Hope for Obesity

VK2735 operates as a dual agonist targeting both glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. The presentation emphasized the drug's remarkable efficacy, particularly in patients treated over a 13-week duration. Patients taking VK2735 experienced a statistically significant weight loss beginning from the very first week and continuing well into the treatment period.

During the trial, it was noted that patients administered VK2735 achieved an average weight reduction of up to 12.2% (which translates to approximately 26.6 pounds) from their baseline weight. This outcome was particularly prominent among participants taking doses higher than 15 mg, hinting at a direct correlation between dose and effectiveness. Unlike many weight-loss medications that tend to show a plateau in results, VK2735 maintained a consistent progression of weight loss throughout the treatment.

Impressive Statistics and Patient Demographics

The Phase 2 trial involved 280 adult participants, all categorized as obese with a Body Mass Index (BMI) of ≥30 kg/m². The demographics represented in the study mirror the typical clinical patient environment, which included a notable prevalence of cardiometabolic risk factors—over half of the subjects reported pre-diabetes.

Of the VK2735 cohort, nearly 97% achieved at least 5% weight loss, with approximately 80% hitting the benchmark of 10% weight loss, a stark contrast to mere 10% and 5% success rates for placebo participants respectively.

Safety and Tolerability Profile

Safety concerns are paramount in any therapeutic development, and VK2735 emerged with a favorable tolerability profile. The majority of treatment-emergent adverse events (TEAEs) reported during the trial were classified as mild to moderate in severity and were predominantly gastrointestinal-related, which typically resolved after continued treatment.

Lead investigator Dr. Parke Joseph Hedges articulated the importance of VK2735’s clinical data, noting the drug's mild side effects and the significant reductions in weight as early as week one, coupled with a manageable safety profile akin to that observed with established dual agonist therapies.

A Step Towards Phase 3 Trials

Viking’s CEO, Dr. Brian Lian, expressed enthusiasm over the data, highlighting its role in shaping future registration studies for VK2735. The findings not only pave the way for VK2735’s transition into Phase 3 trials but also position it as a leading candidate in the obesity drug market, potentially enabling patients to shift from injections to an effective oral tablet formulation.

With the anticipated Phase 3 registration trials on the horizon, VK2735 could soon offer a competitive advantage over existing therapies, meeting the growing demand for accessible weight loss solutions.

Conclusion

The implications of VK2735's success extend beyond mere statistics; they represent hope for individuals battling obesity and the associated health issues. Viking Therapeutics is paving the path toward an innovative future in metabolic disorder treatment with VK2735, and the upcoming phases of clinical trials will be crucial in determining its efficacy and market readiness.

For more detailed insights into the ongoing research and development, visit Viking Therapeutics’ website at www.vikingtherapeutics.com.